Curr Osteoporos Rep (2010) 8:23–27 8. Baron R, Rowadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007;148:2635–43. 9. Bellido T. Downregulation of SOST (sclerostin) by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact 2006;6:358–9. 10. Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009;24:1651–61. 11. Schmidmaier G, Wildemann B. Perspectives: the role of BMPs in current orthopedic practice. IBMS BoneKEy 2009;6:244–53. 12. Govender S, Csimma C, Genant HK, et al. BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002;84A:2123–34. 13. Friedlander GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (BMP-7) in treatment of tibial nonunions. J Bone Joint Surg Am 2001;83A(Suppl 1, Pt 2):S151–58. 14. Burkus JK, Gornet MF, Dickman CA, Zdeblick TA. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 2002;15:337–49. 15. White AP, Vaccaro AR, Hall JA, et al. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop 2007;31:735–41. 16. Coles CP, Gross M. Closed tibial shaft fractures: management and treatment complications. A review of the prospective literature. Can J Surg 2000;43:256–62. 17. Chao EY, Inoue N. Biophysical stimulation of bone fracture repair, regeneration and remodeling. Eur Cell Mater 2003;6:72– 84; discussion 84–85. 18. Singh K, Smucker JD, Gill S, Boden SD. Use of recombinant human bone morphogenetic protein-2 as an adjunct in posterolat- eral lumbar spine fusion: a prospective CT-scan analysis at one and two years. J Spinal Disord Tech 2006;19:416–23. 19. Glassman SD, Dimar JR, Carreon LY, et al. Initial fusion rates with recombinant human bone morphogenetic protein-2/compres- sion resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion. Spine 2005;30:1694–98. 20. Villavicencio AT, Burneikiene S, Nelson EL, et al. Safety of transforaminal lumbar interbody fusion and intervertebral recom- binant human bone morphogenetic protein-2. J Neurosurg Spine 2005;3:436–43. 21. Vaccaro AR, Lawrence JP, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in 27 posterolateral lumbar arthrodesis: a long-term (>4 years) pivotal study. Spine 2008;33:2850–62. 22. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine 2002;27(16 Suppl 1): S40–8. 23. Cosman F. Parathyroid hormone treatment of osteoporosis. Curr Opin Endocrinol Diabetes Obes 2008;15:495–501. 24. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–41. 25. Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrin Metab 2009 Oct 26 [Epub ahead of print] This study demonstrates that the transder- mal delivery of hPTH (1–34) was similar to the subcutaneous injection of hPTH (1–34) in terms of increase in BMD with no significant toxicity. 26. Cormier M, Johnson B, Ameri M, et al. Transdermal delivery of desmopressin using coated microneedle array patch system. J Control Release 2004;97:503–511. 27. Gopalakrishnan V, Hwang S, Loughrey H. Administration of ThPTH to humans using Macroflux transdermal technology results in the rapid delivery of biologically active PTH. J Bone Miner Res 2004;19(Suppl 1):S460. 28. John MR, Haemmerle S, Launonen A, et al. A novel oral parathyroid hormone formulation, PTH134, demonstrated a potential therapeutically relevant pharmacokinetic and safety profile compared with teriparatide s.c. in healthy postmenopausal women after a single dose. Arthritis Rheum 2009;60(Suppl 1): S333. 29. Stewart AF, Cain RL, Burr DB, et al. Six-month daily administra- tion of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1–34, parathyroid hormone-related protein 1– 36, and SDZ-parathyroid hormone 893. J Bone Miner Res 2000;15:1517–25. 30. Horwitz MJ, Tedesco MB, Garcia-Ocaña A, et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab 2010 Jan 8 [Epub ahead of print]. 31. Horwitz MJ, Tedesco MB, Gundberg C, et al. Short-term, high- dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88:569–75.